Notably, mutations in the RAS-RAF-MEK-ERK pathway have been implicated in resistance to conventional chemotherapy, particularly in low-grade serous ovarian cancer (LGSOC). This evidence concerns the gene MAP2K7 and ovarian serous adenocarcinoma.